Stem Cells Archives | Page 174 of 178

[Featured on MarketResearch.com] 4 Key Metrics You Need to Know to Invest in the Cord Blood Sector

March 12, 2015 By Cade Hildreth (CEO) Leave a Comment

MarketResearch.com has posted an article titled, “4 Key Metrics You Need to Know to Invest in the Cord Blood Sector,” featuring BioInformant’s analytics for the cord blood banking market.

An excerpt is included below:

“If you are an investor considering an opportunity within the cord blood market, the market can initially appear technical and confusing. However, if you focus on four key metrics, you can quickly and easily assess the technical attributes that matter, including market size, market potential, market competition, and market growth rates.”

A trusted business partner of ours, MarketResearch.com has been selected by Inc. 5000 Magazine as one of America’s fastest growing private companies.

View full post →

BioInformant iPS Cell Data Featured on Centre for Commercialization of Regenerative Medicine

March 12, 2015 By Cade Hildreth (CEO) Leave a Comment

BioInformant is excited to share that our induced pluripotent stem cell industry analytics have been featured on the “Signals Blog,” published by the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies.

The post, titled Right Turn: Commercializing iPSCs – Infographics, states: “The beauty of an infographic (or two) is it speaks for itself.”

View Full CCRM Post →

My Story: President of a Stem Cell Market Research Firm and a Stem Cell Patient

March 12, 2015 By Cade Hildreth (CEO) 1 Comment

For the past 15 years, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.

As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.

However, it was only recently that I experienced the power of stem cells to impact my own life and health.

[Read more…]

“We’re not made of drugs, we’re made of cells”

March 12, 2015 By Cade Hildreth (CEO) Leave a Comment

Below is a short and simple quote that we say often here at BioInformant…

Remember as you make medical decisions in your life that you are not made of drugs, you are made of cells. The source of every cell in your adult body was originally a stem cell.

The importance of stem cells to you and your capacity to a live longer and healthier life cannot be understated.
[Read more…]

BioInformant Releases Global Induced Pluripotent Stem Cell (iPSC) Industry Report

March 11, 2015 By Cade Hildreth (CEO) Leave a Comment

The iPSC industry is rapidly expanding, following the first iPSC trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, and the announcement of an iPSC cellular therapy clinic scheduled to open in 2019. With iPSC patent dominance continuing to cluster in specific geographic regions, clinical trial and scientific publication trends are giving clear indicators of what may happen in the industry in 2015 and beyond.